Journal article
Association between daptomycin dosing and in-hospital mortality in patients with vancomycin-resistant Enterococcus faecium bloodstream infection
- Abstract:
- Background: Vancomycin-resistant Enterococcus faecium (VREfm) bloodstream infections (BSIs) pose significant management challenges with uncertainties relating to the optimal daptomycin dose for treatment. Methods: A retrospective cohort study of adult patients receiving ≥3 days of definitive treatment for a first episode VREfm BSI between 2015 and 2022 was undertaken. Daptomycin doses were classified as low (≤7.9 mg/kg), medium (8.0 to 9.9 mg/kg) or high (≥10 mg/kg). We aimed to assess the association between daptomycin dose and in-hospital 30-day all-cause mortality in addition to other clinical outcomes (hospital length of stay, transfer to the ICU within 48 hours and microbiological failure). In addition, we undertook a comparative analysis of mortality and other outcomes in vanB VREfm BSIs receiving definitive daptomycin and teicoplanin treatment. Results: A total of 191 patients received definitive daptomycin (n = 111) or teicoplanin (n = 80) therapy and were included in two separate analyses. Of the 111 daptomycin patients, most received high-dose daptomycin (59.5%), with 29.7% and 10.8% receiving medium and low doses, respectively. All-cause 30-day in-hospital mortality was 17.1% and there was no association between daptomycin dose groups and in-hospital 30-day mortality (log rank P = 0.369). Microbiological failure was associated with dose (P = 0.036): 33.3% in the low dose group, 12.1% for medium and 19.7% for high. No mortality difference was observed between vanB VREfm BSIs treated with daptomycin or teicoplanin [adjusted cause-specific hazard ratio 0.67 (95% CI: 0.28–1.59)]. Conclusions: In this contemporary study of predominantly high daptomycin doses, there was no association between daptomycin dose and 30-day in-hospital mortality but we did observe an association with microbiological failure.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.0MB, Terms of use)
-
- Publisher copy:
- 10.1093/jacamr/dlaf172
Authors
- Publisher:
- Oxford University Press
- Journal:
- JAC-Antimicrobial Resistance More from this journal
- Volume:
- 7
- Issue:
- 5
- Article number:
- dlaf172
- Publication date:
- 2025-10-09
- Acceptance date:
- 2025-09-08
- DOI:
- EISSN:
-
2632-1823
- ISSN:
-
2632-1823
- Language:
-
English
- Pubs id:
-
2300641
- Local pid:
-
pubs:2300641
- Source identifiers:
-
3356559
- Deposit date:
-
2025-10-09
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2025
If you are the owner of this record, you can report an update to it here: Report update to this record